UT-MD Anderson Cancer Center: AACR - Lung Cancer Outcomes Significantly Improved With Immunotherapy-Based Treatment Given Before and After Surgery
April 17, 2023
April 17, 2023
HOUSTON, Texas, April 17 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release on April 16, 2023:
* * *
Phase III trial finds 32% lower chance of disease recurrence, progression or death with immunotherapy plus chemotherapy versus chemotherapy alone
* * *
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) an . . .
* * *
Phase III trial finds 32% lower chance of disease recurrence, progression or death with immunotherapy plus chemotherapy versus chemotherapy alone
* * *
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) an . . .